Moreover, in May 2025, the White House issued an Executive Order directing federal agencies to pursue “most favored nation” pricing for certain prescription drugs, under which U.S. prices would be indexed to the lowest prices available in select OECD countries. The White House is currently seeking voluntary pricing concessions from manufacturers, with the potential for administrative action to follow if companies do not engage constructively, creating uncertainty around future pricing and reimbursement that could negatively impact our U.S. revenues and overall business performance. We are also subject to increasing pricing pressure and restrictions on reimbursement imposed by payors. If we fail to obtain and maintain adequate formulary positions and institutional access for our current products and future approved products, we will not be able to achieve a return on our investment and our business, financial condition, results of operations and growth prospects would be materially adversely affected.